Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.

Abstract: 3-vinylquinolines analogs and methods of synthesizing the derivatives/analogs are provided. In particular, the compounds are useful for the treatment of cancer.

Abstract: The present disclosure relates to using a compound as a reactant in one or more chemical reactions for making intermediate compounds or reaction-product compounds that includes at least one cyclic N-halamine precursor group and at least one cationic center. The compound has the general formula (1): Wherein Z is either N or Y and when Z is N then R1 and R2 are each independently selected from a group of methyl, ethyl or n-propyl. When Z is Y then R1 and R2 are both nil and Y is selected from Cl, Br and I. The reaction-product compound may have biocidal activity and/or it may have increased biocidal activity following one or more chemical-modification reactions.

Abstract: Photoactivatable pesticide compounds and methods for the use thereof in the elimination and detection of pests are provided.

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Abstract: The present invention provides compounds of formula (I): wherein A1, A2, A3 and A4 are independently of one another C—H, C—R5, or nitrogen; B1-B2-B3-B4 is —CH2—C?N—CH2—, —CH2—N—CH2—CH2—, —CH2—C?CH—O— or —CH?C—CH2—O—; G1 is oxygen or sulfur; L is a single bond or C1-C8alkylene; R1 is hydrogen, C1-C8alkyl, C1-C8alkylcarbonyl-, C1-C8alkoxy, C2-C8alkenyl, C2-C8alkynyl, C1-C8alkoxy-C1-C8alkyl, aryl or aryl substituted by one to three R6, or R1 is heterocyclyl or heterocyclyl substituted by one to three R6 or C1-C8alkoxycarbonyl-; R2 is hydrogen, C1-C8haloalkyl or C1-C8alkyl; R3 is C1-C8haloalkyl; R4 is aryl or aryl substituted by one to three R6, or R4 is heterocyclyl or heterocyclyl substituted by one to three R6; Y1 is CR7R8, C—O or C?S; Y2, Y3 and Y4 are independently CR7R8, C?O, C?S, N—R9, O, S, SO or SO2; wherein at least two adjacent ring atoms in the ring formed by Y1, Y2, Y3 and Y4 are heteroatoms; each R7 and R8 is independently hydrogen, halogen, C1-C8alkyl, or C1-C8haloalkyl; and R5, R6

Abstract: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

Abstract: A composite oligomeric material includes one or more repeating backbone units. One or more polarizable units are incorporated into or connected to one or more of the one or more repeating backbone units. One or more resistive tails are connected to one or more of the repeating backbone units or to the one or more polarizable units as a side chain on the polarizable unit. The composite oligomer material may be polymerized to form a metadielectric, which may be sandwiched between to electrodes to form a metacapacitor.

Abstract: A method for the oxidation of ethylene to form ethylene oxide which comprises: providing an aqueous stream containing ethylene glycol and impurities; introducing the aqueous stream in a first ion exchange treatment bed to reduce the content of these impurities; determining whether an outlet of the first ion exchange treatment bed has a conductivity greater than about 5 ?S/cm; upon determining that the outlet of the first ion exchange treatment bed has a conductivity greater than about 5 ?S/cm, introducing the outlet of the first ion exchange treatment bed into a second ion exchange treatment bed; and upon determining that the outlet of the first ion exchange treatment bed has a conductivity greater than about 60 ?S/cm, redirecting the introduction of the aqueous stream to the second ion exchange treatment bed and regenerating the first ion exchange bed.

Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Abstract: The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Abstract: The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following general formula (I) as defined herein: (I) or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.

Abstract: A new intermediate for synthesizing 1-substituted-4-[phenyl(propanoyl)amino]piperidine-4-carbonitrile derivatives is laid open. Specifically set out is a method for use of this intermediate in the preparation of remifentanil. The enclosed shorter process offers a greater yield of products with higher purity as compared to methods reported in the prior art.

Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

Abstract: A process of obtaining a purified geometric isomer of an unsaturated macrocyclic compound is disclosed herein. The process is effected by contacting an ion exchange medium comprising silver ions with a mixture comprising at least one geometric isomer of the unsaturated macrocyclic compound, to thereby obtain at least one fraction comprising the purified geometric isomer of the macrocyclic compound. A system configured for performing the process is also disclosed.

Abstract: The present invention relates to a method for producing furfural, including: obtaining a sugar solution containing at least one of a monosaccharide having 5 carbon atoms and a polysaccharide containing the monosaccharide having 5 carbon atoms by carrying out a reaction with a specific resource as a raw material in the presence of a catalyst in a solvent; converting at least one of the monosaccharide and the polysaccharide containing the monosaccharide in the sugar solution into furfural by a dehydration reaction, so as to obtain a reaction solution; and separating the reaction solution into an organic layer and an aqueous layer, wherein an aromatic hydrocarbon solvent having a density of from 0.90 g/cm3 to 1.1 g/cm3 at 25° C. and under atmospheric pressure is used, and wherein the reaction solution is separated at a temperature higher than 90° C. and lower than 150° C.

Abstract: An object of the present invention is to provide an immunopotentiating agent for reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity. Imatinib and/or a salt thereof has the action of reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity, and can be used as an active ingredient for the immunopotentiating agent.

Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

Abstract: Kits for the treatment or prophylaxis of depressed mood are described, for subjects with increased MAO-A levels, excessive crying, or subjects within or beyond the 5-day postpartum period. The kits are used to implement a method by which the subject is administered an antioxidant source on at least the first day of a 3 to 5 day regime; a tryptophan composition on the evening of the penultimate treatment day, simultaneously or following the antioxidant source; and a tyrosine composition the day after the tryptophan composition, on the final treatment day. The kit comprises an antioxidant source which may comprise or be derived from blueberries. Individuals with depressed mood due to perimenopause, alcohol use disorders or withdrawal, or who are up to or beyond 18-months postpartum, may benefit from the kits. The kits described may reduce the likelihood of advancing from depressed mood to depression.